bluebird bio Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : bluebird bio Inc.

BLUE 4.970

0.0%

Jun 2 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: scaram(o)uche	9/8/2016 11:03:47 AM
	of 163

The U.S. Food and Drug Administration is allowing Bluebird to treat beta thalassemia patients with the revamped LentiGlobin gene therapy without requiring the company to start over with new preclinical data. This eliminates a lingering concern on the Street that Bluebird's gene therapy studies would be significantly delayed by the manufacturing changes. thestreet.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next